Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Severe Systemic Lupus Erythematosus Who Have Failed Standard Therapies

NCT06041568 is registered in ClinicalTrials.gov with IGM Biosciences, Inc. as lead sponsor.

NCT NCT06041568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Severe Systemic Lupus Erythematosus Who Have Failed Standard Therapies
Lead sponsor
IGM Biosciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
August 15, 2023
Completion date
January 27, 2025
Enrollment
17 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lupus erythematosus, systemic lupus erythematosus